Barclays Maintains Overweight on Royal Caribbean Gr, Raises Price Target to $361
Barclays analyst Brandt Montour maintains Royal Caribbean Gr (NYSE:RCL) with a Overweight and raises the price target from $324 to $361.
D.R. Horton Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
D.R. Horton, Inc. (NYSE:DHI) will release earnings results for the first quarter, before the opening bell on Tuesday,…
Micron’s Pricing Power Looks Unstoppable As AI Demand Outruns Supply
JP Morgan bullish on Micron (MU) due to AI-driven memory demand and constrained clean-room space; expects 20% bit growth in 2026.
Hospitals Face Profit Squeeze As Policy Risks Grow: Analyst
BofA warns hospitals face profit and volume pressure from policy cuts, favors post-acute care, upgrades Brookdale, and sees select names better positioned to weather challenges.
CarMax Likely To Report Lower Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
CarMax, Inc. (NYSE:KMX) will release earnings results for its third quarter before the opening bell on Thursday, Dec.…
Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Lowers Price Target to $93
Canaccord Genuity analyst Caitlin Roberts maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and lowers the price target from $101 to $93.
JP Morgan Maintains Neutral on GFL Environmental, Lowers Price Target to $46.75
JP Morgan analyst Tami Zakaria maintains GFL Environmental (NYSE:GFL) with a Neutral and lowers the price target from $54 to $46.75.
JP Morgan Maintains Neutral on GFL Environmental, Lowers Price Target to $46.75
JP Morgan analyst Tami Zakaria maintains GFL Environmental (NYSE:GFL) with a Neutral and lowers the price target from $54 to $46.75.
HC Wainwright & Co. Reiterates Buy on Coinbase Global, Maintains $425 Price Target
HC Wainwright & Co. analyst Mike Colonnese reiterates Coinbase Global (NASDAQ:COIN) with a Buy and maintains $425 price target.
Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
Guggenheim analyst Brad Canino reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $40 price target.